IQVIA (IQV) Expected to Announce Earnings on Tuesday

IQVIA (NYSE:IQV) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect IQVIA to post earnings of $2.62 per share and revenue of $3.77 billion for the quarter. IQVIA has set its FY 2025 guidance at 11.700-12.100 EPS.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts expect IQVIA to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Stock Performance

NYSE IQV opened at $153.42 on Monday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $27.05 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.99 and a beta of 1.34. The stock has a 50-day moving average of $167.52 and a two-hundred day moving average of $190.76. IQVIA has a 1-year low of $135.97 and a 1-year high of $252.88.

Analysts Set New Price Targets

Several brokerages recently weighed in on IQV. UBS Group cut their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Truist Financial cut their price objective on IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research report on Thursday, April 10th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Finally, Barclays reissued an “equal weight” rating and set a $170.00 price objective (down from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $237.62.

Hedge Funds Weigh In On IQVIA

An institutional investor recently raised its position in IQVIA stock. Brighton Jones LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 244.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,575 shares of the medical research company’s stock after purchasing an additional 2,537 shares during the quarter. Brighton Jones LLC’s holdings in IQVIA were worth $703,000 as of its most recent filing with the SEC. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.